Wells Fargo lowered the firm’s price target on Doximity (DOCS) to $45 from $55 and keeps an Overweight rating on the shares. The firm notes low visibility was a known unknown pre-Q3, but pharma caution proved greater than expected, driving fewer upfronts and slower conversions. Shares at about $20 look overdone, but sentiment may take time to recover, Wells adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity: Rebounding Pharma Momentum, Emerging AI Upside, and Attractive Valuation Support Renewed Growth Buy Thesis
- Doximity upgraded to Neutral from Underweight at JPMorgan
- Buy Rating on Doximity: Near‑Term Timing Headwinds Create an Attractive Entry Point Amid Durable Growth and Margin Strength
- Doximity: Buy Rating Reaffirmed as Attractive Valuation and Emerging AI Growth Offset Near‑Term Macro Headwinds
- Doximity: Resilient Fundamentals and AI-Driven Growth Support Buy Rating Despite Temporary Pharma Budget Delays